Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S7KQ
|
||||
| Former ID |
DCL000319
|
||||
| Drug Name |
Hematide
|
||||
| Indication | Anemia [ICD9: 280-285; ICD10:D50-D64] | Phase 3 | [551985] | ||
| Company |
Affymax Inc; Takeda Pharmaceutical Co Ltd.
|
||||
| CAS Number |
CAS 910576-32-8
|
||||
| Target and Pathway | |||||
| Target(s) | Erythropoietin Receptor | Target Info | Agonist | [531837], [532210], [537308] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | ||||
| EPO signaling pathway | |||||
| WikiPathways | EPO Receptor Signaling | ||||
| References | |||||
| Ref 531837 | Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events. Exp Hematol. 2012 Jul;40(7):575-87. | ||||
| Ref 532210 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | ||||
| Ref 537308 | Anemia in chronic kidney disease: status of new therapies. Curr Opin Nephrol Hypertens. 2009 Mar;18(2):112-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.